C. Murakata

发表

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia.

S. Akinaga, Y. Shiotsu, H. Mizoguchi, 2000, Blood.

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.

H. Saya, S. Akinaga, Takeshi Takahashi, 2009, Cancer research.

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

J. Isaacs, C. Murakata, T. Angeles, 1999, Cancer research.

Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis

N. Neff, M. Miller, C. Murakata, 1998, Neuroscience.

Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C.

I. Takahashi, T. Tamaoki, H. Nakano, 1990, The Journal of pharmacology and experimental therapeutics.

Binding Signaling Molecules Antitumor Activity via Selective Depletion of Hsp 90 Vivo in KF 25706 , a Novel Oxime Derivative of Radicicol , Exhibits

L. Neckers, S. Soga, S. Akinaga, 1999 .

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

L. Neckers, S. Soga, S. Akinaga, 2000, Blood.

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

L. Neckers, S. Soga, S. Akinaga, 2000 .

Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a and its mechanism of action

T. Ashizawa, S. Akinaga, K. Gomi, 2004, Cancer Chemotherapy and Pharmacology.

Synthesis of [7ß-methoxy 11C]methoxy staurosporine for imaging protein kinase C localization in the brain

M. Senda, S. Akinaga, C. Murakata, 1996 .

Mixed lineage kinase activity of indolocarbazole analogues.

D. Bozyczko‐Coyne, C. Murakata, T. Angeles, 2002, Bioorganic & medicinal chemistry letters.

Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives.

S. Akinaga, T. Tsujita, Y. Yamashita, 2014, Bioorganic & medicinal chemistry letters.

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

S. Akinaga, Y. Yamashita, C. Murakata, 2015, Molecular Cancer Therapeutics.

Stereospecific antitumor activity of radicicol oxime derivatives

M. Shimizu, Sreenath V. Sharma, L. Neckers, 2001, Cancer Chemotherapy and Pharmacology.

Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients

S. Akinaga, Y. Shiotsu, Takashi Suzuki, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Stereoselective total synthesis of the glycosyl phosphatidylinositol (GPI) anchor of Trypanosoma brucei.

C. Murakata, T. Ogawa, 1992, Carbohydrate research.

Stereoselective synthesis of glycobiosyl phosphatidylinositol, a part structure of the glycosyl-phosphatidylinositol (GPI) anchor of Trypanosoma brucei.

C. Murakata, T. Ogawa, 1992, Carbohydrate research.

A total synthesis of GPI anchor of trypanosoma brucei

C. Murakata, T. Ogawa, 1991 .

Synthetic studies on glycophosphatidylinositol anchor: a highly efficient synthesis of glycobiosyl phosphatidylinositol through H-phosphonate approach

C. Murakata, T. Ogawa, 1991 .

A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models

S. Akinaga, Y. Shiotsu, T. Kuwabara, 2007, Breast Cancer Research and Treatment.

Glycolipids with nonreducing end α‐mannosyl residues that have the potential to activate invariant Vα19 NKT cells

C. Murakata, T. Kinoshita, Y. Hirabayashi, 2007 .

Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds.

T. Tamaoki, M. Okabe, C. Murakata, 1999, Journal of Medicinal Chemistry.

Derives de thiadiazoline

T. Tsujita, C. Murakata, R. Nakai, 2004 .

Chiral Route to Some Alkaloids through Asymmetric Iodolactonization

C. Murakata, S. Takano, K. Ogasawara, 1981 .

Synthesis and antitumor activity of duocarmycin derivatives: modification at C-8 position of A-ring pyrrole compounds bearing the simplified DNA-binding groups.

T. Tamaoki, K. Gomi, M. Okabe, 2000, Bioorganic & medicinal chemistry.

Synthetic study on glycophosphatidyl inositol (GPI) anchor of Trypanosoma brucei: glycoheptaosyl core.

C. Murakata, T. Ogawa, 1990 .

K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.

C. Murakata, S. Nakanishi, Y. Matsuda, 1987, Biochemical and biophysical research communications.

In vitro and in vivo effects of KT6352, a derivative of indolocarbazole compounds, on murine megakaryocytopoiesis.

S. Akinaga, Y. Shiotsu, H. Mizoguchi, 1998, Experimental hematology.

Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives.

T. Ashizawa, H. Nakano, M. Okabe, 1992, Biochemistry.

Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation

J. Virkkala, M. Saarma, A. M. Camoratto, 2000, The Journal of Neuroscience.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

N. Neff, J. Isaacs, A. M. Camoratto, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells.

M. Gottesman, P. Lazarovici, C. Murakata, 1995, European journal of cancer.

KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

L. Neckers, S. Soga, S. Akinaga, 1999, Cancer research.

Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.

N. Neff, M. Glicksman, C. Dionne, 1997, Journal of medicinal chemistry.

CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo.

D. Sengelaub, N. Neff, R. Oppenheim, 1998, Journal of neurobiology.

CEP‐751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti‐tumor activity

N. Neff, J. Isaacs, A. Maroney, 1997, International journal of cancer.

Prodrug esters of the indolocarbazole CEP-751 (KT-6587).

C. Murakata, J. Mallamo, E. Shek, 1998, Bioorganic & medicinal chemistry letters.

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.

H. Saya, S. Akinaga, Takeshi Takahashi, 2009, Cancer research.

Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

S. Akinaga, Y. Shiotsu, T. Akiyama, 2003, Journal of medicinal chemistry.